OpenBilldrug price receipt

NADAC week of 2026-10-14

LOPINAVIR-RITONAVR 200-50 MG TB

For 30 tablets

Pharmacies pay

$133.95 filed

30 × $4.46491 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$142.84 filed

30 × $4.76133 per EA, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18


The spread

1.1× estimated

Medicare paid 1.1× what pharmacies pay.

Part D averages every strength and form sold under “Lopinavir-Ritonavir” / “Lopinavir/Ritonavir” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$159.04 estimated

$133.95 + $20.09 (15%) + $5.00 fee per fill = $159.04

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

LOPINAVIR-RITONAVR 200-50 MG TB is how the CMS NADAC file names this product. The FDA NDC Directory lists it as lopinavir and ritonavir.

FDA gives its dosage form as tablet, film coated and its route as oral.

Its labelers, the companies named on the label, are Camber Pharmaceuticals, Inc. and Laurus Labs Limited.

FDA lists it under 2 Established Pharmacologic Classes: Cytochrome P450 3A Inhibitor and Protease Inhibitor.

The NADAC file of 2026-10-14 prices it under 2 NDCs (National Drug Codes).

NADAC classes it as a generic drug (rate-setting class G), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $133.95 for 30 tablets (30 × $4.46491 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

All 2 NDCs

Compared with its class

The middle of its 2 NDCs’ NADAC prices is $4.46491 per EA filed.

Of the 7 other products in FDA’s Cytochrome P450 3A Inhibitor class priced per EA, 6 have a higher middle NADAC price and 1 a lower one. The one in the middle is PREZCOBIX 800 MG-150 MG TABLET, at $79.99382 per EA filed (eff. 2026-09-23).

Of the 11 other products in FDA’s Protease Inhibitor class priced per EA, 6 have a higher middle NADAC price and 5 a lower one. The one in the middle is NORVIR 100 MG TABLET, at $8.3489 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What Medicare paid

Medicare Part D paid $142.84 for 30 tablets, at an average of $4.76133 per EA in 2024 (2024-01-01 to 2024-12-31) for “Lopinavir-Ritonavir” and “Lopinavir/Ritonavir”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 4,261 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why is the comparison with Medicare for LOPINAVIR-RITONAVR 200-50 MG TB labelled estimated?
Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Lopinavir-Ritonavir / Lopinavir/Ritonavir: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on generic name.